Today: 7 February 2026
Subscribe
Browse Category

NYSE:PFE News 30 November 2025 - 13 December 2025

Pfizer (PFE) Stock After Hours on Dec. 12, 2025: Dividend Update, FDA “Black Box” Headline, Analyst Forecasts — What to Know Before the Next Market Open

Pfizer (PFE) Stock After Hours on Dec. 12, 2025: Dividend Update, FDA “Black Box” Headline, Analyst Forecasts — What to Know Before the Next Market Open

(SEO): Pfizer stock (NYSE: PFE) held firm after the bell on Dec. 12, 2025. Here’s the full roundup of today’s headlines, analyst targets, and what to watch before the next market session. Pfizer, Inc. (NYSE: PFE) wrapped up Friday’s session (December 12, 2025) with a modest gain, then traded narrowly higher in extended hours as investors weighed a dense mix of shareholder-return news (dividend), regulatory headlines tied to COVID vaccines, and fresh oncology trial results—plus at least one notable analyst price-target cut. One important calendar note upfront: December 13, 2025 is a Saturday, and U.S. stock markets are closed. So
13 December 2025
····
Pfizer (PFE) Stock After Hours on Dec. 12, 2025: Dividend Update, FDA Vaccine Warning Headlines, and What to Watch Before the Next Market Open

Pfizer (PFE) Stock After Hours on Dec. 12, 2025: Dividend Update, FDA Vaccine Warning Headlines, and What to Watch Before the Next Market Open

Pfizer Inc. (NYSE: PFE) ended the Friday, December 12, 2025 session slightly higher—and moved only modestly in after-hours trading—after a busy day of headline-driven catalysts. Investors weighed a newly declared $0.43 quarterly dividend, fresh FDA-related reporting tied to COVID-19 vaccine labeling, and late-stage oncology data involving Pfizer’s breast-cancer drug Tukysa (tucatinib). Reuters+3StockAnalysis+3Pfizer+3 Below is a detailed, publication-ready breakdown of what happened after the bell on 12/12/2025 and what to know heading into the next U.S. market session (note: U.S. stock markets do not hold a regular session on Saturday, December 13, 2025). Pfizer stock after the bell: the numbers investors
13 December 2025
···
Pfizer (PFE) Stock Outlook After the November 21 FDA Win: Obesity Deals, Cost Cuts and a 6.7% Dividend Yield

Pfizer (PFE) Stock Outlook After the November 21 FDA Win: Obesity Deals, Cost Cuts and a 6.7% Dividend Yield

As of December 11, 2025, Pfizer Inc. (NYSE: PFE) is trying to rewrite its post‑COVID story. The stock trades around $25.66 per share, after a choppy year of guidance upgrades, obesity-drug M&A, aggressive cost cuts and fresh regulatory wins in oncology and rare disease. Since November 21, 2025, a cluster of headlines — from an FDA approval in bladder cancer to a new GLP‑1 weight‑loss deal and expanding cost‑saving measures — has shifted how analysts and investors think about Pfizer’s earnings power going into 2026 and beyond. Pfizer stock today: price, yield and recent performance Pfizer’s board declared a $0.43
11 December 2025
·····
Pfizer (PFE) Stock Premarket Today, Dec. 11, 2025: Marshall Wace Exit, Obesity Drug Deals and 2026 Guidance in Focus

Pfizer (PFE) Stock Premarket Today, Dec. 11, 2025: Marshall Wace Exit, Obesity Drug Deals and 2026 Guidance in Focus

Pfizer (NYSE: PFE) heads into Thursday’s session with its share price hovering around yesterday’s close, as investors digest a flurry of news on cost cuts, obesity drug deals, and a big hedge fund trimming its stake. As of around 6:05 a.m. ET on Thursday, December 11, real‑time feeds put Pfizer stock near $25.78, roughly flat versus Wednesday’s close of $25.78 after a 1.78% gain in the prior session.StockAnalysis+1 The stock has traded between $20.92 and $27.69 over the past 12 months, and daily volume on Wednesday was around 43–44 million shares, close to its recent average.Investing.com+1 Despite its recent rebound,
11 December 2025
····
Pfizer Stock Today: Obesity Deal, Cancer Breakthroughs and Job Cuts Shape PFE’s 2025 Outlook

Pfizer Stock Today: Obesity Deal, Cancer Breakthroughs and Job Cuts Shape PFE’s 2025 Outlook

As of the session on 10 December 2025, Pfizer Inc. (NYSE: PFE) is trading around $25.5 per share, up modestly on the day and still far below its 2021 peak. The stock now combines a high dividend yield of roughly 6.5–7% with one of the cheapest valuations in big pharma, making it a focal point for income and value investors alike. CoinCentral Today’s move in PFE is being driven by a cluster of fresh catalysts: Below is a detailed, news‑driven look at Pfizer stock today — including the latest news, forecasts and analysis relevant to 10 December 2025. 1. PFE
10 December 2025
····
Pfizer (PFE) Stock After Hours on December 9, 2025: Obesity Pill Deal, RSV Questions, and What to Watch Before the Opening Bell

Pfizer (PFE) Stock After Hours on December 9, 2025: Obesity Pill Deal, RSV Questions, and What to Watch Before the Opening Bell

Pfizer Inc. (NYSE: PFE) finished a volatile Tuesday session on December 9, 2025 under pressure, then stabilized in after-hours trading as investors digested a big new obesity-drug licensing deal and fresh headlines around RSV therapies. With the next U.S. market session opening on December 10, 2025, traders in Pfizer stock are lining up the key catalysts that could drive PFE’s next move. How Pfizer Stock Traded on December 9, 2025 During regular trading on December 9, Pfizer shares slipped again: The weakness continues a choppy pattern for Pfizer stock in late 2025, with shares trading closer to the bottom half
10 December 2025
····
Pfizer Stock (PFE) on December 8, 2025: Price, Dividend, New Drug Data and 2025–2030 Forecast

Pfizer Stock (PFE) on December 8, 2025: Price, Dividend, New Drug Data and 2025–2030 Forecast

Pfizer Inc. (NYSE: PFE) heads into mid‑December 2025 as one of the market’s most hotly debated “high-yield value” healthcare stocks. The share price has stabilized around the mid‑$20s after a bruising multi‑year slide, even as the company delivers solid earnings, unveils promising new clinical data, and doubles down on obesity drugs and AI-driven cost cutting. At the same time, investors are weighing a looming patent cliff, a tougher regulatory climate for vaccines, and legal setbacks tied to Pfizer’s Seagen acquisition. Below is a structured look at where Pfizer stock stands today and how major analysts and models see it over
8 December 2025
····
Pfizer (PFE) Stock on December 6, 2025: Metsera Deal, 2025 Guidance and What Wall Street Expects Next

Pfizer (PFE) Stock on December 6, 2025: Metsera Deal, 2025 Guidance and What Wall Street Expects Next

Pfizer Inc. (NYSE: PFE) is ending 2025 in better shape than it started, but investors are still debating whether the stock is a high‑yield value opportunity or a classic “value trap.” As of Friday, December 5, 2025, Pfizer shares closed at $26.03, up 1.28% on the day and marking a third straight session of gains. The stock sits about 6% below its 52‑week high of $27.69 (hit on October 3) and roughly 24% above its April low of $20.92.MarketWatch+1 At the same time, Pfizer offers an unusually rich dividend yield of about 6.6%, a fortress‑like balance sheet for a big
6 December 2025
·····
Pfizer (PFE) Stock Today: Price, Metsera Obesity Deal, 2025–2026 Forecast and Key Risks

Pfizer (PFE) Stock Today: Price, Metsera Obesity Deal, 2025–2026 Forecast and Key Risks

Pfizer, Inc. (NYSE: PFE) is back in focus on December 5, 2025, as investors weigh a near‑7% dividend yield, fresh analyst commentary, a major obesity‑drug acquisition and a slate of upcoming guidance that will shape expectations for 2026. Below is a detailed, news‑driven look at Pfizer stock today, including the latest price action, current Wall Street forecasts, and the biggest opportunities and risks now dominating the conversation. Pfizer stock price today: where things stand As of late trading on December 5, 2025, Pfizer shares are: Volatility is relatively low: one recent analysis pegs Pfizer’s rolling one‑year beta at just 0.59,
5 December 2025
····
Pfizer (PFE) Stock on December 2, 2025: Price, Metsera Deal, New FDA Risks and 2026 Outlook

Pfizer (PFE) Stock on December 2, 2025: Price, Metsera Deal, New FDA Risks and 2026 Outlook

As of late trading on Tuesday, December 2, 2025, Pfizer (NYSE: PFE) shares change hands around $25.10, down roughly 0.7% on the day and sitting in the middle of their 52‑week range of $20.92–$27.69.Yahoo Finance+1 The stock carries a dividend yield close to 7%, reflecting a generous payout but also lingering skepticism about the pharma giant’s growth post‑COVID.Pfizer+1 Today’s price is being shaped by a dense mix of headlines: a fresh FDA push to tighten vaccine oversight, a legal setback for Pfizer’s Seagen unit, the completion of a $10 billion obesity-drug acquisition, and earlier this quarter, upgraded 2025 profit guidance and new oncology approvals.Pfizer+4Investopedia+4Reuters+4 Below is
2 December 2025
·····
Pfizer (PFE) Stock Outlook Before the December 1, 2025 Open: Price, Metsera Obesity Deal, Dividend Payout and Wall Street Forecasts

Pfizer (PFE) Stock Outlook Before the December 1, 2025 Open: Price, Metsera Obesity Deal, Dividend Payout and Wall Street Forecasts

As U.S. markets prepare to reopen on Monday, December 1, 2025, Pfizer Inc. (NYSE: PFE) heads into the new week trading in a tight range but surrounded by a flurry of fresh analysis, institutional activity and strategic news from November 28–30. At the close on Friday, November 28, 2025, Pfizer shares finished around $25.74, giving the drugmaker a market capitalization of roughly $146 billion.Stock Titan With U.S. equity markets shut over the weekend, that closing print is the key reference point for investors going into Monday’s session. In this pre‑open update, we break down Pfizer’s latest stock price action, key
30 November 2025
·····
Pfizer (PFE) Stock on November 30, 2025: Institutional Buying, Metsera Deal and a 6.7% Dividend Yield

Pfizer (PFE) Stock on November 30, 2025: Institutional Buying, Metsera Deal and a 6.7% Dividend Yield

Pfizer Inc. (NYSE: PFE) is back in the spotlight as of November 30, 2025. Fresh regulatory filings show new institutional buying, analysts are nudging price targets higher, and the company has closed a multibillion‑dollar obesity deal while reshaping its post‑pandemic pipeline. This article pulls together the most relevant current Pfizer stock news as of November 30, 2025, and explains what it may mean for PFE shareholders. Key Takeaways Pfizer Stock Today: Price, Performance and Valuation Pfizer’s shares last closed at about $25.74 on November 28, 2025, according to exchange data and several market data providers. StockAnalysis Over the past 12
30 November 2025
·····
1 … 7 8 9 10

Stock Market Today

Seagate (STX) stock jumps nearly 6% as Citi hikes target — what to watch next week

Seagate (STX) stock jumps nearly 6% as Citi hikes target — what to watch next week

7 February 2026
Seagate shares rose 5.9% to $429.32 Friday after Citigroup raised its price target to $480 and reiterated a buy rating. The gain ended a two-day slide but left the stock 6.6% below its Feb. 3 high. CEO Dave Mosley sold 20,000 shares on Feb. 2 under a pre-arranged plan, SEC filings show. U.S. jobs and inflation data next week are seen as key tests for tech stocks.
Cummins (CMI) stock price rebounds after earnings whipsaw as investors eye data-center power demand

Cummins (CMI) stock price rebounds after earnings whipsaw as investors eye data-center power demand

7 February 2026
Cummins shares jumped 6.8% to $577.73 Friday, recovering from a nearly 9% post-earnings drop the day before. The company reported Q4 revenue up 1% to $8.54 billion, took a $218 million charge tied to its hydrogen business, and guided for 2026 EBITDA of 17–18% of sales. Demand for data center generators offset weakness in North American truck markets. Analyst reaction was mixed; Truist raised its price target.
Corning stock hits first record close since 2000 as jobs, CPI data loom

Corning stock hits first record close since 2000 as jobs, CPI data loom

7 February 2026
Corning shares surged 8.3% to $122.16 Friday, their highest close since the dot-com era, after Meta agreed to buy up to $6 billion in fiber-optic cables. The stock is up 40% since late 2025, fueled by strong first-quarter guidance and AI data-center demand. Insiders sold shares following the rally, SEC filings show. Investors await next week’s U.S. jobs and inflation data for rate signals.
Go toTop